In contrast to VEGFRs, expression of KIT, FGFR1, FGFR2, FGFR4 and PDGFRA (additional targets of a small-molecule tyrosine kinase inhibitor lenvatinib associated with oncogenesis and maintenance of the tumor microenvironment in several types of cancer) was largely elevated among ACC tumors analyzed in this study. This evidence concerns the gene FGFR4 and adrenal cortex carcinoma.